SEC 13F Intelligence

Managers / Q4 2021 · view latest →

ISZO CAPITAL MANAGEMENT LP

CIK 0001607925 · 590 MADISON AVENUE, 21ST FLOOR, NEW YORK, NY, 10022 · 646-775-4394

Reported Value
$190M
Q4 2021
Positions
7
Filings on Record
22
2019–present window
Filed
Feb 14, 2022
original filing

Summary

Iszo Capital Management LP reported $190M in U.S.-listed holdings across 7 positions for Q4 2021.

The portfolio is heavily concentrated: Avid Bioservices alone accounts for 33.9% of reported value.

Compared with Q3 2021, the fund opened 1 new position and exited 1.

Portfolio Metrics

Turnover
+30.8%
vs prior filed quarter
Largest Position
+33.9%
Avid Bioservices
New / Exited
1 / 1
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $92MQ4 ’18Q1 ’19: $61MQ2 ’19: $64MQ3 ’19: $76MQ3 ’19Q4 ’19: $69MQ1 ’20: $65MQ2 ’20: $57MQ2 ’20Q3 ’20: $74MQ4 ’20: $96MQ1 ’21: $212MQ1 ’21Q2 ’21: $275MQ3 ’21: $227MQ4 ’21: $190MQ4 ’21Q1 ’22: $84MQ2 ’22: $64MQ3 ’22: $58MQ3 ’22Q4 ’22: $7MQ1 ’23: $19MQ2 ’23: $18MQ2 ’23Q3 ’23: $2MQ4 ’23: $2Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 80.0%Other: 20.0%
  • Common Stock · 80.0% · $152M
  • Other · 20.0% · $38M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
GLOBAL CORD BLOOD CORPORATIONEW+1.0K1.0K+$4,000$4,000
NOTVQINOTIV INCADDED+951.3K1.28M+$44M$54M
MTBLYRENREN INCSOLD OUT−36.4K0−$506,000$0
LFCRLANDEC CORPADDED+276.8K1.93M+$6M$21M
NAM TAI PPTY INCADDED+782.0K6.67M−$99M$38M
AVID BIOSERVICES INCTRIMMED−138.6K2.21M+$14M$64M
CCELCRYO-CELL INTL INCHELD−13.6K482.9K−$411,000$6M
XPELXPEL INCHELD+0103.9K−$787,000$7M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2021

7 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1AVID BIOSERVICES INCCOM33.90%$64M2.21M
2NOTVQINOTIV INChistory →COM28.22%$54M1.28M
3NAM TAI PPTY INCSHS19.96%$38M6.67M
4LFCRLANDEC CORPhistory →COM11.24%$21M1.93M
5XPELXPEL INChistory →COM3.73%$7M103.9K
6CCELCRYO-CELL INTL INChistory →COM2.95%$6M482.9K
7GLOBAL CORD BLOOD CORPORATIOSHS0.00%$4,0001.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2023$2M1Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$2M3Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$18M3Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$19M10May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$7M7Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$58M6Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$64M6Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$84M5May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$190M7Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$227M7Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$275M8Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$212M5May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$96M6Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$74M5Nov 17, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$57M10Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$65M10May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$69M3Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$76M4Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$64M2Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$61M5May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$92M5Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.